• Explore /
  • Poster
  • / Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

Abstract Poster

Authors

null

Martin J. Van Den Bent

Erasmus MC Cancer Center, Rotterdam, Netherlands

Martin J. Van Den Bent , Pim French , Marica Eoli , Juan M. Sepúlveda , Anna Maria Elisabeth Walenkamp , Jean-Sebastien Frenel , Enrico Franceschi , Paul M. Clement , Michael Weller , Iris de Heer , Jim Looman , Jyotirmoy Dey , Scott Krause , Hao Xiong , Peter J Ansell , Sarah Nuyens , Maarten Spruyt , Joana Brilhante , Thierry Gorlia , Vassilis Golfinopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT02343406

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2023)

DOI

10.1200/JCO.2018.36.15_suppl.2023

Abstract #

2023

Poster Bd #

181

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

Mebendazole in recurrent glioblastoma: Results of a phase 2 randomized study.

Mebendazole in recurrent glioblastoma: Results of a phase 2 randomized study.

First Author: Nandini Sharrel Menon

First Author: Yoshitaka Narita

First Author: Daniela Annenelie Bota

First Author: Dorota Goplen